Abstract:Background: Pharmacologically targeting the STING pathway offers a novel approach to cancer immunotherapy. However, small-molecule STING agonists face challenges such as poor tumor accumulation, rapid clearance, and short-lived effects within the tumor microenvironment, thus limiting their therapeutic potential. To address the challenges of poor specificity and inadequate targeting of STING in breast cancer treatment, herein, we report the design and development of a targeted liposomal delivery system modified with the tumor-targeting peptide iRGD (iRGD-STING-PFP@liposomes). With LIFU irradiation, the liposomal system exploits acoustic cavitation, where gas nuclei form and collapse within the hydrophobic region of the liposome lipid bilayer (transient pore formation), which leads to significantly enhanced drug release. Methods: Transmission electron microscopy (TEM) was used to investigate the physicochemical properties of the targeted liposomes. Encapsulation efficiency and in vitro release were assessed using the dialysis bag method, while the effects of iRGD on liposome targeting were evaluated through laser confocal microscopy. The CCK-8 assay was used to investigate the toxicity and cell growth effects of this system on 4T1 breast cancer cells and HUVEC vascular endothelial cells. A subcutaneous breast cancer tumor model was established to evaluate the tumor-killing effects and therapeutic mechanism of the newly developed liposomes. Results: The liposome carrier exhibited a regular morphology, with a particle size of 232.16 ± 19.82 nm, as indicated by dynamic light scattering (DLS), and demonstrated low toxicity to both HUVEC and 4T1 cells. With an encapsulation efficiency of 41.82 ± 5.67%, the carrier exhibited a slow release pattern in vitro after STING loading. Targeting results indicated that iRGD modification enhanced the system's ability to target 4T1 cells. The iRGD-STING-PFP@liposomes group demonstrated significant tumor growth inhibition in the subcutaneous breast cancer mouse model with effective activation of the immune system, resulting in the highest populations of matured dendritic cells (71.2 ± 5.4%), increased presentation of tumor-related antigens, promoted CD8+ T cell infiltration at the tumor site, and enhanced NK cell activity. Conclusions: The iRGD-STING-PFP@liposomes targeted drug delivery system effectively targets breast cancer cells, providing a new strategy for breast cancer immunotherapy. These findings indicate that iRGD-STING-PFP@liposomes could successfully deliver STING agonists to tumor tissue, trigger the innate immune response, and may serve as a potential platform for targeted immunotherapy.

Development of STING probes and visualization of STING in multiple tumor types

Development of 18F-Labeled Acridone Analogue for Tumor Imaging Via Stimulator of Interferon Genes Targeting

Preclinical Evaluation of 131I/18F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging

18F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor

18 F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor

A Novel 18F-Labeled Agonist for PET Imaging of Stimulator of Interferon Gene Expression in Tumor-Bearing Mice

STING-targeted PET Tracer for Early Assessment of Tumor Immunogenicity in Colorectal Cancer after Chemotherapy.

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

Discovery of Novel Thieno[2,3-d]imidazole Derivatives As Agonists of Human STING for Antitumor Immunotherapy Using Systemic Administration.

Probiotic Engineering and Targeted Sonoimmuno-Therapy Augmented by STING Agonist.

A novel STING agonist with systemic and durable anti-tumour activity

STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging.

Abstract 6644: A Comprehensive in Vitro and in Vivo System to Evaluate STING Agonist Efficacy in Cancer Therapeutics

Immu-19. Preclinical Therapeutic Activity And Pet Imaging Of Sting Agonist 8803 In Glioblastoma

A STING pathway-activatable contrast agent for MRI-guided tumor immunoferroptosis synergistic therapy

Engineered PLGA Microparticles for Long-Term, Pulsatile Release of STING Agonist for Cancer Immunotherapy

Low-Intensity Focused Ultrasound-Responsive Phase-Transitional Liposomes Loaded with STING Agonist Enhances Immune Activation for Breast Cancer Immunotherapy

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy

Potentiating the Systemic Immunity by Bacteria‐Delivered Sting Activation in a Tumor Microenvironment

Novel Emerging Nano-Assisted Anti-Cancer Strategies Based on the STING Pathway

Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.